Ischemic postconditioning alters the gene expression pattern of the ischemic heart

Experimental Biology and Medicine

Volumn 239, Issue 2, 2014, Pages 141-150

  Csonka, Csaba ^a,b   Szucs, Gergo ^a   Varga Orvos, Zoltán ^c   Bencsik, Péter ^b   Csont, Tamás ^a,b   Zvara, Ágnes ^c   Puskás, László G ^c   Ferdinandy, Péter ^b,d  

^a UNIVERSITY OF SZEGED   (Hungary)

^b PHARMAHUNGARY GROUP   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

gene ontology; heart; microarray; Postconditioning; rat

Indexed keywords

GENE ONTOLOGY; HEART; MICROARRAY; POSTCONDITIONING; RAT;

ANIMALS; DOWN-REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; ISCHEMIC POSTCONDITIONING; MALE; METABOLIC PHENOMENA; MYOCARDIUM; RATS; RATS, WISTAR; RNA; UP-REGULATION;

EID: 84893931612     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213511017     Document Type: Article

References (35)

1. Ferdinandy P,Schulz R,Baxter GF.Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.Pharmacol Rev. 2007;59:418-58.
2. Ovize M,Baxter GF,Di Lisa F,Ferdinandy P,Garcia-Dorado D,Hausenloy DJ,Heusch G,Vinten-Johansen J,Yellon DM,Schulz R.Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.Cardiovasc Res. 2010;87:406-23.
3. Na HS,Kim YI,Yoon YW,Han HC,Nahm SH,Hong SK.Ventricular premature beat-driven intermittent restoration of coronary blood flow reduces the incidence of reperfusion-induced ventricular fibrillation in a cat model of regional ischemia.Am Heart J. 1996;132:78-83.
4. Zhao ZQ,Corvera JS,Halkos ME,Kerendi F,Wang NP,Guyton RA,Vinten-Johansen J.Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning.Am J Physiol Heart Circ Physiol. 2003;285:H579-88.
5. Hausenloy DJ.Signalling pathways in ischaemic postconditioning.Thromb Haemost. 2009;101:626-34.
6. Heusch G,Boengler K,Schulz R.Cardioprotection: nitric oxide, protein kinases, and mitochondria.Circulation. 2008;118:1915-9.
7. Onody A,Zvara A,Hackler L,Vigh L,Ferdinandy P,Puskas LG.Effect of classic preconditioning on the gene expression pattern of rat hearts: a DNA microarray study.FEBS Lett. 2003;536:35-40.
8. Csonka C,Szilvassy Z,Fulop F,Pali T,Blasig IE,Tosaki A,Schulz R,Ferdinandy P.Classic preconditioning decreases the harmful accumulation of nitric oxide during ischemia and reperfusion in rat hearts.Circulation. 1999;100:2260-6.
9. Csonka C, Kupai K, Kocsis GF, Novák G, Fekete V, Bencsik P, Csont T and Ferdinandy P. Measurement of myocardial infarct size in preclinical studies. J Pharmacol Toxicol Methods 2010;61:163-70.
10. Puskas LG,Nagy ZB,Giricz Z,Onody A,Csonka C,Kitajka K,Hackler L,Zvara A,Ferdinandy P.Cholesterol diet-induced hyperlipidemia influences gene expression pattern of rat hearts: a DNA microarray study.FEBS Lett. 2004;562:99-104.
11. Dennis G,Sherman BT,Hosack DA,Yang J,Gao W,Lane HC,Lempicki RA.DAVID: Database for Annotation, Visualization, and Integrated Discovery.Genome Biol. 2003;4:P3-P3.
12. Sherman BT,Huang da W,Tan Q,Guo Y,Bour S,Liu D,Stephens R,Baseler MW,Lane HC,Lempicki RA.DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis.BMC Bioinformatics. 2007;8:426-426.
13. Menesi D,Kitajka K,Molnar E,Kis Z,Belleger J,Narce M,Kang JX,Puskas LG,Das UN.Gene and protein expression profiling of the fat-1 mouse brain.Prostaglandins Leukot Essent Fatty Acids. 2009;80:33-42.
14. van der Spek PJ,Kremer A,Murry L,Walker MG.Are gene expression microarray analyses reliable? A review of studies of retinoic acid responsive genes.Genomics Proteomics Bioinformatics. 2003;1:9-14.
15. Lopaschuk GD,Stanley WC.Glucose metabolism in the ischemic heart.Circulation. 1997;95:313-5.
16. Calvani M,Reda E,Arrigoni-Martelli E.Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions.Basic Res Cardiol. 2000;95:75-83.
17. Lopaschuk GD.Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?.Coron Artery Dis. 2001;12:S8-11.
18. Lopaschuk GD,Ussher JR,Folmes CD,Jaswal JS,Stanley WC.Myocardial fatty acid metabolism in health and disease.Physiol Rev. 2010;90:207-58.
19. Boengler K,Heusch G,Schulz R.Nuclear-encoded mitochondrial proteins and their role in cardioprotection.Biochim Biophys Acta. 2011;1813:1286-94.
20. Gorbe A,Varga ZV,Kupai K,Bencsik P,Kocsis GF,Csont T,Boengler K,Schulz R,Ferdinandy P.Cholesterol diet leads to attenuation of ischemic preconditioning-induced cardiac protection: the role of connexin 43.Am J Physiol Heart Circ Physiol. 2011;300:H1907-13.
21. Schulz R,Boengler K,Totzeck A,Luo Y,Garcia-Dorado D,Heusch G.Connexin 43 in ischemic pre- and postconditioning.Heart Fail Rev. 2007;12:261-6.
22. Kuo HC,Cheng CF,Clark RB,Lin JJ,Lin JL,Hoshijima M,Nguyen-Tran VT,Gu Y,Ikeda Y,Chu PH,Ross J,Giles WR,Chien KR.A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I(to) and confers susceptibility to ventricular tachycardia.Cell. 2001;107:801-13.
23. Kupai K,Csonka C,Fekete V,Odendaal L,van Rooyen J,Marais de W,Csont T,Ferdinandy P.Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: role of peroxynitrite.Am J Physiol Heart Circ Physiol. 2009;297:H1729-35.
24. Palmieri F.The mitochondrial transporter family (SLC25): physiological and pathological implications.Pflugers Arch. 2004;447:689-709.
25. de Boer RA,Voors AA,Muntendam P,van Gilst WH,van Veldhuisen DJ.Galectin-3: a novel mediator of heart failure development and progression.Eur J Heart Fail. 2009;11:811-7.
26. de Boer RA,Yu L,van Veldhuisen DJ.Galectin-3 in cardiac remodeling and heart failure.Curr Heart Fail Rep. 2010;7:1-8.
27. Schroen B,Heymans S,Sharma U,Blankesteijn WM,Pokharel S,Cleutjens JP,Porter JG,Evelo CT,Duisters R,van Leeuwen RE,Janssen BJ,Debets JJ,Smits JF,Daemen MJ,Crijns HJ,Bornstein P,Pinto YM.Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy.Circ Res. 2004;95:515-22.
28. Dickstein K,Cohen-Solal A,Filippatos G,McMurray JJ,Ponikowski P,Poole-Wilson PA,Stromberg A,van Veldhuisen DJ,Atar D,Hoes AW,Keren A,Mebazaa A,Nieminen M,Priori SG,Swedberg K.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).Eur J Heart Fail. 2008;10:933-89.
29. Yoshida M,Suzuki A,Yamamoto H,Noguchi S,Mizuno Y,Ozawa E.Dissociation of the complex of dystrophin and its associated proteins into several unique groups by n-octyl beta-D-glucoside.Eur J Biochem. 1994;222:1055-61.
30. Hack AA,Groh ME,McNally EM.Sarcoglycans in muscular dystrophy.Microsc Res Tech. 2000;48:167-80.
31. Ozawa E,Mizuno Y,Hagiwara Y,Sasaoka T,Yoshida M.Molecular and cell biology of the sarcoglycan complex.Muscle Nerve. 2005;32:563-76.
32. Bereczki E,Gonda S,Csont T,Korpos E,Zvara A,Ferdinandy P,Santha M.Overexpression of biglycan in the heart of transgenic mice: an antibody microarray study.J Proteome Res. 2007;6:854-61.
33. Csont T,Ferdinandy P.Letter by Csont and Ferdinandy regarding article, "Biglycan is required for adaptive remodeling after myocardial infarction".Circulation. 2008;118:e521-e521.
34. Csont T,Gorbe A,Bereczki E,Szunyog A,Aypar E,Toth ME,Varga ZV,Csonka C,Fulop F,Santha M,Ferdinandy P.Biglycan protects cardiomyocytes against hypoxia/reoxygenation injury: role of nitric oxide.J Mol Cell Cardiol. 2010;48:649-52.
35. Hausenloy DJ,Erik Botker H,Condorelli G,Ferdinandy P,Garcia-Dorado D,Heusch G,Lecour S,van Laake LW,Madonna R,Ruiz-Meana M,Schulz R,Sluijter JP,Yellon DM,Ovize M.Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.Cardiovasc Res. 2013;98:7-27.